Daily FNArena News - Australia

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

NAB Offers Value, Says DJ Carmichael

Apr 04 2011

FNArena’s Sentiment Indicator doesn’t show National Australia Bank as the highest rated of the majors, but DJ Carmichael sees value at current levels.


Brokers Update Stock Convictions

Apr 01 2011

As we enter the June quarter, brokers have begun reassessing those stocks for which they hold a high Buy or Sell conviction.


Australian Investors Concerned About An Uncertain Market

Apr 01 2011

Investors in Australia are not lining up to allocate more cash to the share market, our March Survey has revealed.


Cricket Australia To Launch IPO

Apr 01 2011

Recent poor performances have left Cricket Australia in a sorry financial state. Taking a lead from the Brisbane Broncos, CA has decided to encourage fans to invest in their own team.


BHP And Woodside? Don’t Think So

Mar 31 2011

Woodside shares have shot up recently on rumours of a takeover by BHP. Citi analysts can’t see any reason why BHP would be interested.


Australian Homebuyer Confidence A Disaster

Mar 31 2011

A six-monthly survey by mortgage insurer Genworth Financial has found homebuyers would have become more confident since September if not for the spate of natural disasters.


Sensis Strategy No Sure Winner For Telstra

Mar 30 2011

Telstra briefed the market on a new strategy for directories and online division Sensis but brokers continue to question the potential of the new approach.


Focus On Alacer Gold’s Copler Project

Mar 29 2011

An update from Alacer Gold shows development of the Copler project in Turkey continues to advance.


A Funding Boost For Australian Banks

Mar 29 2011

Not mortgage securities again? Yes – but this time in the far less risky form of covered bonds, which will reduce the banks’ reliance on expensive offshore funding.


Biotron A Potential Re-Rating Story

Mar 29 2011

Southern Cross Equities expects favourable clinical trial results from anti-viral drug developer Biotron.



Analyse The Market From A Different Angle